BioSpace News Archive

Complete, home-based solution for diagnosing respiratory sleep disorders approved for commercialization in Europe and other CE Mark geographies

Immunomedics, Inc. , (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that Trodelvy (sacituzumab govitecan-hziy) is now available through major specialty distributors in the United States and that the first patient was treated with commercial product on April 29, 2020. Trodelvy is the first anti-Trop-2 ADC recently approved by the U.S.

Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced that the abstract accepted as an ePoster presentation at Digestive Disease Week (DDW) 2020 Virtual Meeting may now be viewed at the online meeting portal . The ePoster includes preclinical data from the Company’s microbio

Surgical navigation startup Centerline Biomedical, Inc. (Centerline), a Cleveland Clinic spin-off company, has announced the successful completion of the first in a series clinical cases in the US

Enteris BioPharma, Inc. , a biotechnology company developing innovative drug products built around its proprietary delivery technologies and a wholly-owned subsidiary of SW

SutroVax , a biopharmaceutical company dedicated to the development of superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced the appointment of Andrew Guggenhime as Chief Financial Officer and Chief Business Officer. In this role, Mr. Guggenhime

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25%, its product candidate for the short-term treatment of the signs

Teva and Celltrion Healthcare Announce the Launch of TRUXIMA ® (rituximab-abbs) Injection for Rheumatoid Arthritis, the Only Biosimilar to Rituxan ® (rituximab) Available in the United States for This Indication TRUXIMA is also now available for the treatment of Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis) and Microscopic Polyangiitis (MPA)

Company provides updates on recent regulatory, clinical, operational, and business developments

ALR Technologies Inc. (“ALRT” or the “Company”) (OTCQB: ALRT), the diabetes management company, is pleased to announce that its common shares are now trading on the OTCQB Venture Market. We believe that graduating to the OTCQB Venture Market is an important step for the company’s future and that it will bring better visibility and liquidity within the investment community. The OTCQB Venture Market is well suited for developing companies. To b